[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341214-105":59,"doc-detail-341214-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","n-myc-impairs-innate-immune-signaling-in-high-grade-serous-ovarian-carcinoma","N-MYC impairs innate immune signaling in high-grade serous ovarian carcinoma","","High-grade serous ovarian cancer (HGSC) is characterized by immunologically cold tumors lacking tumor-infiltrating lymphocytes. MYCN (N-MYC) shows among the highest levels of expression across human cancers and correlates with reduced antitumor immune features. In HGSC models, N-MYC represses basal and induces IFN type I signaling, lowering chemokine expression and T cell chemoattraction. Mechanistically, N-MYC suppresses tumor-cell intrinsic STING signaling via reduced STING oligomerization and inhibits RIG-I–like signaling by blocking MAVS aggregation and mitochondrial localization. Single-cell RNA sequencing of patient samples links the MYCN transcriptional program to diminished type I IFN signaling, supporting N-MYC as an immunotherapy target.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/n-myc-impairs-innate-immune-signaling-in-high-grade-serous-ovarian-carcinoma/341214/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/n-myc-impairs-innate-immune-signaling-in-high-grade-serous-ovarian-carcinoma/341214.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the relationship between N-MYC and type I interferon signaling in HGSC?","Question",{"text":112,"@type":113},"N-MYC represses basal and inhibits induction of IFN type I signaling in HGSC cell lines and shows a strong negative association with type I IFN signaling in patient single-cell data.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does N-MYC suppress innate immune signaling pathways?",{"text":117,"@type":113},"N-MYC inhibits tumor cell–intrinsic STING signaling by reducing STING oligomerization, and it blunts RIG-I–like receptor signaling by preventing MAVS aggregation and mitochondrial localization.",{"name":119,"@type":110,"acceptedAnswer":120},"Why are HGSC tumors described as immunologically cold, and why does this matter?",{"text":121,"@type":113},"HGSC is often associated with immunologically cold tumors devoid of tumor-infiltrating lymphocytes, and this immunosuppressive state corresponds to limited benefit from immunotherapy, motivating targets that can restore innate immune signaling.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341214,1790471554,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","CANCER  \nN-MYC impairs innate immune signaling in high-grade serous ovarian carcinoma  \nAlex Miranda1,2†‡, Swetansu Pattnaik3†, Phineas T. Hamilton1,2†, Monica Alvaro Fuss1, Shreena Kalaria1, Céline M. Laumont1,2, Julian Smazynski1, Monica Mesa4‡, Allyson Banville1,2, Xinpei Jiang5, Russell Jenkins6, Israel Cañadas5, Brad H. Nelson1,2,4*  \nHigh-grade serous ovarian cancer (HGSC) is a challenging disease, especially for patients with immunologically“cold” tumors devoid of tumor-infiltrating lymphocytes (TILs). We found that HGSC exhibits among the highest levels of MYCN expression and transcriptional signature across human cancers, which is strongly linked to diminished features of antitumor immunity. N-MYC repressed basal and induced IFN type I signaling in HGSC cell lines, leading to decreased chemokine expression and T cell chemoattraction. N-MYC inhibited the induction of IFN type I by suppressing tumor cell–intrinsic STING signaling via reduced STING oligomerization, and by blunting RIG-I–like receptor signaling through inhibition of MAVS aggregation and localization in the mitochondria. Single-cell RNA sequencing of human clinical HGSC samples revealed a strong negative association between cancer cell–intrinsic MYCN transcriptional program and type I IFN signaling. Thus, N-MYC inhibits tumor cell–intrinsic innate immune signaling in HGSC, making it a compelling target for immunotherapy of cold tumors.  \ncopyright © 2024 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. no claim to original U.S.  \nGovernment Works. distributed under a creative commons Attribution license 4.0 (cc BY) .  \nINTRODUCTION  \nHigh-grade serous ovarian carcinoma (HGSC) is the most common form of ovarian cancer, accounting for 70 to 80% of ovarian cancer deaths. Survival rates for HGSC have improved little since the 1980s, highlighting an urgent need for new treatments (1). Despite the poor outcomes overall, there is strong evidence that the immune system promotes favorable prognosis in some patients (2) . Nonetheless, HGSC cancer cells and the tumor microenvironments they engender exhibit numerous immunosuppressive features (3), and clinical trials of immunotherapy for this disease have failed to demonstrate substantial benefit (4, 5) .  \nA key process regulating antitumor immunity in many cancer types involves the sensing of cytoplasmic nucleic acids by the cGAS [cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) synthase]/STING [stimulator of interferon (IFN) genes, encoded by TMEM173] and RIG-I (retinoic acid inducible gene I, encoded by DDX58)–like receptor (RLR) pathways (6). Activation of these pathways in tumor cells induces the production of type I IFNs via the serine/threonine kinase TBK1 (TANK-binding kinase 1) and transcription factor IRF3 (IFN regulatory factor 3) (7–11). Autocrine signaling through IFN type I receptors activates the transcription factor signal transducer and activator of transcription 1 (STAT1), leading to expression ofIFN-stimulated genes (ISGs), including multiple immunostimulatory cytokines and chemokines ( 12) . Recent evidence demonstrates the impact of cancer cell–intrinsic activation of these pathways on the tumor microenvironment and response to  \n1deeley Research centre, Bc cancer, victoria, Bc v8R 6v5, canada. 2department of Medical Genetics, University of British columbia, vancouver, Bc v6t 1Z3, canada. 3the Kinghorn cancer centre and cancer division, Garvan institute of Medical Research, 370 victoria St, darlinghurst, nSW, Australia. 4department of Biochemistry and Microbiology, University of victoria, victoria, Bc v8P 3e6, canada. 5nuclear dynamics and cancer Program, Fox chase cancer center, Philadelphia, PA, USA. 6Massachusetts General hospital, harvard Medical School, Boston, MA, USA.  \n*[corresponding author. email: bnelson@bccrc.ca](corresponding author. email: bnelson@bccrc.ca)[ ](corresponding author. email: bnelson@bccrc.ca)†these","cbCairk9GKph2vdX","https://ap.wps.com/l/cbCairk9GKph2vdX","pdf",9821813,18,"English","# Introduction\n## IFN type I signaling and innate immune sensing pathways\n## Immunosuppression and clinical limits of immunotherapy in HGSC","[{\"question\":\"What is the relationship between N-MYC and type I interferon signaling in HGSC?\",\"answer\":\"N-MYC represses basal and inhibits induction of IFN type I signaling in HGSC cell lines and shows a strong negative association with type I IFN signaling in patient single-cell data.\"},{\"question\":\"How does N-MYC suppress innate immune signaling pathways?\",\"answer\":\"N-MYC inhibits tumor cell–intrinsic STING signaling by reducing STING oligomerization, and it blunts RIG-I–like receptor signaling by preventing MAVS aggregation and mitochondrial localization.\"},{\"question\":\"Why are HGSC tumors described as immunologically cold, and why does this matter?\",\"answer\":\"HGSC is often associated with immunologically cold tumors devoid of tumor-infiltrating lymphocytes, and this immunosuppressive state corresponds to limited benefit from immunotherapy, motivating targets that can restore innate immune signaling.\"}]","N-MYC impairs innate immune signaling in high-grade serous ovarian carcinoma | PDF",1790040939,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd25f6120b9421fdc07fb40dda94207a.webp",983,1250,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e9d690b00ff342f66fc510ae797fbb1.webp",982,1249,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2884119b4433f42d3ea0103b8bffa042.webp",981,1248,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1d2f277f71beea69463dbd9c8819e867.webp",980,1247]